Advertisements

Stocking Stuffers

 

Actinium Pharmaceuticals Inc. (Delaware) (ATNM) Stock Quote

Detailed Quote for Actinium Pharmaceuticals Inc. (Delaware) (ATNM)
$ 0.206   0.0027 (+1.33%) Volume: 1.26m 8:00 PM EST 13-Dec-2019
After Hours:  $ 0.206 0.00 (0.00%) Volume: 8.15k 6:59 PM EST 13-Dec-2019
Today 5d 1m 3m 1y more
Last Price
0.206
Change $
0.0027
Change %
1.33%
Tick
  
Bid
N/A
Bid Size
0
Ask
N/A
Ask Size
0
Open
0.225
High
0.225
Low
0.2015
Prev Close
0.2033
Last Trade
12/13/19
Volume
1.26m
52 Wk Hi
0.708500027
52 Wk Low
0.189999997
Market Cap
33.93m
Ex-Div Date
N/A
Div Rate
N/A
Yield
N/A
Shares
164,701,167
EPS (TTM)
-0.170000001
PE Ratio
N/A
Exchange
NYSE American
News and Media for Actinium Pharmaceuticals Inc. (Delaware) (ATNM)
Sector News | Topic News
News for Actinium Pharmaceuticals Inc. (Delaware) (ATNM)
Wed, Dec 11, 2019
8:54 AM Actinium Pharmaceuticals (ATNM) Investor Presentation - Slideshow - SeekingAlpha
Mon, Dec 09, 2019
6:10 AM Actinium Pharmaceuticals Highlights 86% Response Rate and 71% MRD Negative Rate in Actimab-A CLAG-M Combination Trial in Patients with Relapsed or Refractory AML at ASH 2019 Annual Meeting - PR Newswire
6:00 AM Actinium Pharmaceuticals Announces Phase 3 SIERRA Trial Dosimetry Results Support Low Dose Iomab-B for Targeted Lymphodepletion Prior to Adoptive Cell Therapy - PR Newswire
Sun, Dec 08, 2019
12:09 PM Penny Stocks On Robinhood To Watch This Week Presenting Key Data - PennyStocks.com
Thu, Nov 07, 2019
4:05 PM Actinium Pharmaceuticals to Present at the 25th Annual BIO-Europe\u00AE 2019 International Partnering Conference - PR Newswire
Wed, Nov 06, 2019
9:15 AM Actinium Announces Interim Results from Phase 1 Actimab-A CLAG-M Combination Trial in Patients with Relapsed or Refractory AML Accepted for Presentation at ASH 2019 - PR Newswire
9:00 AM Actinium Pharmaceuticals to Present New Clinical Findings from SIERRA Trial Supporting the Iomab-ACT Program for Targeted Lymphodepletion for CAR-T and Adoptive Cell Therapies at ASH 2019 - PR Newswire
Mon, Oct 28, 2019
8:20 AM Actinium Announces Positive Interim Results from Iomab-B Pivotal Phase 3 SIERRA Trial at 50% of Total Patient Enrollment - PR Newswire
Fri, Oct 25, 2019
1:09 PM Actinium Pharmaceuticals Inc is Among the Companies in the Biotechnology Industry With the Lowest Sales per Share (ATNM, PFNX, NVTA, EBS, ABBV) - NetworkNewsWire
Thu, Oct 24, 2019
7:00 AM Actinium to Announce Interim Results from Pivotal Phase 3 SIERRA Trial on Conference Call Scheduled for Monday, October 28th - PR Newswire
Thu, Oct 17, 2019
12:54 PM Highest Sales per Share in the Biotechnology Industry Detected in Shares of AbbVie Inc (ABBV, EBS, NVTA, PFNX, ATNM) - NetworkNewsWire
Mon, Sep 30, 2019
8:00 AM Actinium Announces Participation at the 2019 Cell & Gene Meeting on the Mesa - PR Newswire
Mon, Sep 23, 2019
8:00 AM Actinium Announces Iomab-B Poster Selected for Honorable Distinction Award at the 2019 Society of Hematologic Oncology Annual Meeting from Nearly Four Hundred Abstracts - PR Newswire
Mon, Sep 16, 2019
8:00 AM Actinium Pharmaceuticals to Present at the Sachs 19th Annual Biotech in Europe Forum for Global Partnering & Investment - PR Newswire
Thu, Sep 05, 2019
8:30 AM Actinium Pharmaceuticals to Present at the Rodman & Renshaw 21st Annual Global Investment Conference - PR Newswire
Thu, Aug 08, 2019
9:12 AM Sell-siders trim views on Inogen after Q2 miss and guidance cut - SeekingAlpha
More News for ATNM >>
Filings for Actinium Pharmaceuticals Inc. (Delaware) (ATNM)
Mon, Nov 25, 2019
3:00 AM Other definitive proxy statements - Form DEF 14A
3:00 AM Current report pursuant to Section 13 or 15(d) - Form 8-K
Fri, Nov 15, 2019
3:00 AM Preliminary proxy statement providing notification matters to be brought to a vote - Form PRE 14A
Tue, Nov 12, 2019
3:00 AM General form for quarterly reports under Section 13 or 15(d) - Form 10-Q
More Filings for ATNM >>

Tags for Actinium Pharmaceuticals Inc. (Delaware)

Research stocks or mutual funds related to Actinium Pharmaceuticals Inc. (Delaware) by keywords or tags. Find companies that have a similar focus to ATNM. The keywords below have been associated to ATNM by either user submission or electronic means.